FTSE 100 news / Companies and sectors / Convatec
Convatec news analysis
Convatec (LSE: CTEC) is in the FTSE 100. 17 of the last 21 days had relevant coverage.
Latest: Tuesday 20 October 2026
+7.0 from 1 relevant story. Coverage was limited to a report on a director buying Convatec shares, which leans positive as an insider vote of confidence.
Tone over time
Coverage of Convatec improved between 30 September 2026 and 20 October 2026
Daily news tone, from −10 (clearly bad) to +10 (clearly good). Gaps are days with no relevant stories.
Tone rose 2.3-fold from 3 to 7 between 30 Sep and 20 Oct. Its low was −2 in 9 Oct.
- 11
- 22
- 33
12 days of 17 had fewer than 3 relevant stories, so those points are thin evidence. Numbered markers are the days with the strongest single headline (key below). This is the tone of coverage, not a share price.Source: MarketFrame news analysis
| day | Tone |
|---|---|
| 30 Sep | 3 |
| 1 Oct | −2 |
| 2 Oct | 7 |
| 3 Oct | – |
| 4 Oct | – |
| 5 Oct | 5 |
| 6 Oct | 6 |
| 7 Oct | 6 |
| 8 Oct | 5 |
| 9 Oct | −2 |
| 10 Oct | 3 |
| 11 Oct | – |
| 12 Oct | 7 |
| 13 Oct | 3 |
| 14 Oct | 0 |
| 15 Oct | 5 |
| 16 Oct | −2 |
| 17 Oct | 1 |
| 18 Oct | 2 |
| 19 Oct | – |
| 20 Oct | 7 |
Day by day
| Day | Tone | Stories | What the coverage was about |
|---|---|---|---|
| Tuesday 20 October 2026 | +7.0 | 1 | Coverage was limited to a report on a director buying Convatec shares, which leans positive as an insider vote of confidence. |
| Monday 19 October 2026 | – | 0 | |
| Sunday 18 October 2026 | +2.0 | 1 | Coverage was limited to Morgan Stanley keeping its GBP 2.88 price target on Convatec stock. |
| Saturday 17 October 2026 | +1.3 | 2 | Coverage was limited to two analysis pieces on Convatec, one on its buyback set against a stretched payout and one on whether the shares trade below fair value on cash flow. |
| Friday 16 October 2026 | −1.8 | 2 | Coverage was light and mostly about the share price sitting well below a quoted target of 305.44p, plus a vague piece on a regulatory-news entry. |
| Thursday 15 October 2026 | +4.5 | 4 | Coverage was mainly about a non-executive director buying shares, which reads as a vote of confidence. |
| Wednesday 14 October 2026 | +0.3 | 4 | Coverage was mixed: a former employee is seeking £366M in a patent profit-share claim and a costly InnovaMatrix write-down was discussed. |
| Tuesday 13 October 2026 | +2.5 | 2 | Coverage was light and mostly about Convatec's share price and its recovery story. |
| Monday 12 October 2026 | +7.0 | 1 | Coverage focused on Convatec's Accelerate strategy, which is described as setting out a path to faster organic growth. |
| Sunday 11 October 2026 | – | 0 | |
| Saturday 10 October 2026 | +3.0 | 1 | Coverage was a single piece noting that Convatec shares edged higher in a quiet advance. |
| Friday 9 October 2026 | −2.2 | 2 | Coverage centred on a 1.54% share price fall alongside reported ostomy findings, and on whether new product launches can offset a reimbursement hit. |
| Thursday 8 October 2026 | +5.3 | 1 | Coverage centred on Convatec's continuing share buyback as its Accelerate plan unfolds. |
| Wednesday 7 October 2026 | +6.0 | 3 | Coverage centred on Convatec expanding its USD 200 million share buyback and the launch of its Cure Aqua product, both seen in a positive light. |
| Tuesday 6 October 2026 | +6.3 | 4 | Coverage centred on the launch of Cure Aqua in North America and a new CEO's plan to push R&D after a long turnaround. |
| Monday 5 October 2026 | +5.2 | 2 | Coverage centred on the launch of Cure Aqua in North America and a look at whether Convatec can sustain its margin progress while its buyback continues. |
| Sunday 4 October 2026 | – | 0 | |
| Saturday 3 October 2026 | – | 0 | |
| Friday 2 October 2026 | +7.2 | 2 | Coverage was mildly positive, led by Bank of America raising its price target on Convatec to 300p. |
| Thursday 1 October 2026 | −2.0 | 1 | Coverage focused on Convatec continuing to return cash to shareholders while a US wound care price cut weighs on it. |
| Wednesday 30 September 2026 | +3.0 | 3 | Coverage was light, with a market report noting Convatec shares advanced and outperformed the market on Tuesday. |
Sector: Pharma and healthcare